**FINAL WEEKS TO REGISTER**



Register Online!
**biobankingcongress.com**

Register by June 23 and SAVE UP to $450!

**October 25-27, 2017**
Nashville Marriott at Vanderbilt University
**Nashville, TN**

9TH INTERNATIONAL

# Leaders in BIObanking Congress 2017

## Advancing Personalized Medicine - One Patient Biospecimen at a Time

CORPORATE SPONSORS

Agena BIOSCIENCE

BioProcessing Solutions powered by RUCDR

Brooks LIFE SCIENCE SYSTEMS

**KEYNOTE PRESENTATION:**

A Brief Introduction to the *All of Us* Research Program

**Joshua C. Denny, M.D., MS**, Professor, Biomedical Informatics & Medicine; Director, Vanderbilt Center for Precision Medicine; Vice President, Personalized Medicine, Vanderbilt University Medical Center

## Join Us in Nashville

**THE 2017 TOUR WILL VISIT CHTN:**

Cooperative Human Tissue Network's Vanderbilt University division

CO-HOSTED BY

VANDERBILT UNIVERSITY MEDICAL CENTER

CHTN COOPERATIVE HUMAN TISSUE NETWORK

Cambridge HEALTHTECH Institute

A Division of Cambridge Innovation Institute

FINAL WEEKSTO REGISTER

COVER
Short Courses
Current Agenda
Hotel & Travel
Sponsor & Exhibit
Pricing & Registration

Register Online!
biobankingcongress.com

Cambridge Healthtech Institute's Ninth International

# Leaders in BIObanking Congress 2017

October 25-27, 2017 | Nashville, TN

## Advancing Personalized Medicine - One Patient Biospecimen at a Time

The goal of personalized medicine has ushered in the transition from empirical medicine to molecular medicine. Thus, during research, biobanks are key infrastructures for biomedical R&D because at one time or another, these biospecimens have been stored in a biobank. Well-annotated biospecimens and their associated clinical data accelerate translational and clinical research discoveries. However, high-throughput molecular sequencing and increased biosample variety have introduced significant informatics challenges for biobanking infrastructures. Meanwhile, the lack of high-quality biospecimens both stalls projects and limits research advances.

Cambridge Healthtech Institute's Ninth International Leaders in Biobanking Congress addresses biospecimen science, management, and applications, bringing together biomedical and biopharmaceutical researchers, regulators, biorepository managers and practitioners to investigate the best strategies for effective use of biospecimens within today's cutting-edge biomedical research, leading to the goal of personalized medicine.

# PRE-CONFERENCE SHORT COURSES*

## WEDNESDAY, OCTOBER 25 **8:00 AM SHORT COURSE REGISTRATION**

**8:30 - 11:30 am**

## SC1: From Donor to Discovery - Post-Mortem Sample Biobanking

### Pre-Conference Short Course Description

Biobanking has been key in new medical advances; however, living donors can only contribute tissues that do not directly affect their quality of life. Post-mortem biobanking allows for the collection of whole organs and tissues, significantly increasing sample yield and tissue type. With post-mortem biobanking comes new challenges, such as the donation and consent process, recovery of organs and tissues as well as processing and storage of biosamples. This course covers each of these via experts in the field.

### Learning Objectives

- Discuss how to obtain donors
- Understand who can and how to recover post-mortem tissues
- Learn how to recover in a timely fashion to ensure that tissue quality is premiere
- Share the impact donation has on donor families/researchers
- Highlight how researchers utilize the post-mortem tissue and the importance of the tissue
- Navigate the steps necessary for creating a post-mortem biobank - IRB/registries

### Who Should Attend

- Biobank representatives wishing to reach new markets and expand their knowledge of other types of biobanking
- Technicians wishing to see other options in the biobanking field
- Individuals interested in learning how post-mortem biobanking works
- Individuals who want to hear from donor families

### Instructors

*Kayla E. Gray, Research Recovery and Processing Specialist, Eversight*
*Sarah Gray, Director, Communications, American Association of Tissue Banks; Author, A Life Everlasting: The Extraordinary Story of One Boy's Gift to Medical Science*
*Charles J. Pivoney, CEBT, MBA, Chief Innovations Officer, Eversight*
*Additional Instructors to be Announced*

### Course Length and Time

3.0 hours (0.3 CEUs) 8:30 – 11:30 am

### Course Date

*October 25, 2017*
**FEE:** $699 Commercial/$399 Academic, Government, Hospital-Affiliated
**ACPE#:** 0778-0000-17-108-L01-P
**Released:** 10/17.

**11:30 am - 12:30 pm Bridging Luncheon for Short Course Participants**

### ACCREDITATION

Barnett International is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. **For each course, participants will receive 3.0 hours (0.3 CEUs)** of continuing education credit for full participation, including the completion of a pre-test, post-test, and program evaluation. Barnett International will email ACPE statements within three weeks of program completion.

# PRE-CONFERENCE SHORT COURSES*

## WEDNESDAY, OCTOBER 25 **8:00 AM** SHORT COURSE REGISTRATION

**12:30 - 3:30 pm**

## SC2: Lean Six Sigma and the Biorepository - Synchronicity in the Simplest Form

### Pre-Conference Short Course Description

The academic human biorepository, centered on the collection of human solid tissue tumors and uninvolved tissue, is perhaps one of the most underfunded resources, due to many moving parts and regulatory requirements. Funding agencies rarely understand the financial requirements of this resource. The biorepository function is an interesting mix of scientific research and business that is often forced into changing operational models yearly to ensure sustainability. The biorepository must be agile enough to operate in the changing landscape of healthcare institutions and regulatory requirements, maintain operational efficiency, continuously identify and overcome challenges and make improvements. Against a backdrop of economic uncertainty and reduced funding for research, the biorepository must find ways to engage staff, keep operations stable and build a strong foundation using proven techniques, such as Six Sigma and Lean Six Sigma.

### Learning Objectives

- Learn the concept of Lean Six Sigma and how to engage staff to contribute to the success of the biorepository
- Understand the requirements and scalability of Lean Six Sigma
- Collaborate and communicate the design, methods and implementation of the Lean Six Sigma process

### Who Should Attend

- Biorepository managers
- Biorepository technicians
- Biorepository IT personnel
- Biorepository directors

### Instructors

*Colleen M. Mitchell, Joint Biorepository Operations Manager, Indiana University Genetics Biobank and Indiana Biobank*

*Kerry R. Wiles, Program Director, Cooperative Human Tissue Network and Vanderbilt University Medical Center Tissue Repository, Vanderbilt University*

### Course Length and Time

3.0 hours (0.3 CEUs) 12:30 – 3:30 pm

### Course Date

*October 25, 2017*

**FEE:** $699 Commercial/$399 Academic, Government, Hospital-Affiliated

**ACPE#:** 0778-0000-17-109-L01-P

**Released:** 10/17.

** Separate registration required*

**ACCREDITATION**

Barnett International is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. **For each course, participants will receive 3.0 hours (0.3 CEUs)** of continuing education credit for full participation, including the completion of a pre-test, post-test, and program evaluation. Barnett International will email ACPE statements within three weeks of program completion.

# 2017 CURRENT AGENDA

## WEDNESDAY, OCTOBER 25

**8:00 am Short Course Registration**

**8:30 - 11:30 Pre-Conference Short Course***
**SC1: From Donor to Discovery - Post-Mortem Sample Biobanking**
** Separate registration required. See page 2 for details.*

**11:30 Bridging Luncheon for Short Course Participants**

**12:30 - 3:30 pm Pre-Conference Short Course***
**SC2: Lean Six Sigma and the Biorepository - Synchronicity in the Simplest Form**
** Separate registration required. See page 2 for details.*

**3:00 Conference Registration**

### Onsite Laboratory Tour and Reception:

**CHTN: Cooperative Human Tissue Network of Vanderbilt University Medical Center**
*(Limited to 50 participants) (4:00-6:50)*

**4:00 Shuttle Bus from Conference Hotel to Welcome Reception and Laboratory Tour**
Tour participants will be dropped off at Medical Center North, Round Wing, directly adjacent to the building where the reception will be hosted (Langford Auditorium).

Hosted by CHTN, Vanderbilt University Medical Center

**4:30 Welcome Reception**

**5:00 Laboratory Tour at CHTN**

**6:50 Close of Tour**

**7:00 Shuttle Bus from Laboratory Tour to Conference Hotel**
Tour participants will be picked up at Medical Center North, Round Wing.

*For updates and to reserve your place, please visit BiobankingCongress.com*

## THURSDAY, OCTOBER 26

**7:00 am Registration and Morning Coffee**

### IT TAKES A VILLAGE

**8:30 Organizer's Welcome Remarks**
*Mary Ann Brown, Executive Director, Conferences, Cambridge Healthtech Institute*

**8:35 Chairperson's Opening Remarks**
*Mary Kay Washington, M.D., Ph.D., Professor, Pathology, Vanderbilt University Medical Center*

**8:45 KEYNOTE PRESENTATION:**

**A Brief Introduction to the *All of Us* Research Program**
*Joshua C. Denny, M.D., MS, Professor, Biomedical Informatics & Medicine; Director, Vanderbilt Center for Precision Medicine; Vice President, Personalized Medicine, Vanderbilt University Medical Center*
The Precision Medicine Initiative *All of Us* Research Program's goal is to sustainably improve the health of individuals and populations. PMI will collect comprehensive data from a diverse cohort of more than 1 million individuals through the application of new precision medicine knowledge obtained from rigorous research studies. All data will be housed in a secure cloud with diverse tools to easily access the data.

**9:30 The Pathologists' Perspectives on Biobanking**
*Sarah M. Dry, M.D., Vice Chair, Biobanking and Research Services; Director, Anatomic and Surgical Pathology; Director, Center for Pathology Research Services; Director, Pathology Research Portal; Director, Translational Pathology Core Laboratory; Department of Pathology, UCLA David Geffen School of Medicine*
In today's -omic environment, biosample acquisition, storage and testing are critical for inclusion in clinical trials, selection of optimal therapies and proper diagnosis. High-quality biobanking operations are essential to accurate testing. This talk summarizes developments in biobank quality standards and accreditation, reviews continuing challenges faced by pathologists in their role as caretakers of biosamples, discusses inclusion of donor/patient perspectives into biobanking practice and considers some emerging developments.

**10:00 Ensuring Sample Integrity through Genetic Fingerprinting & Quality Screening**
Sponsored by Agena Bioscience
*Robin Everts, Ph.D., Staff Scientist, Scientific Affairs, Agena Bioscience*
It is estimated that 1 in 200 specimens is misidentified. Many mistakes occur outside a facility's chain of custody and traditional checks will not detect them. Downstream, DNA quality can cause even pre-qualified samples to fail analysis. Learn techniques to prevent incorrect results and avoid wasting time and money.

**10:15 Coffee Break in the Exhibit Hall with Poster Viewing**

**11:00 Management of Specimens Collected in Complex Biomarker-Driven Clinical Trials: Integration of Patient, Molecular, and Specimen Information to Drive Precision Medicine**
*Michael Tanen, Director, Clinical Biomarker Specimen Management, Translational Medicine, Merck Research Laboratories*
Recent advances in translational and personalized medicine initiatives have led to a marked increase in biomarker-driven research objectives within clinical trials. These advances will require innovative mechanisms and best practices to manage collected biomarker specimens. Improved capabilities are necessary to develop integrated data sources that will inform the selection and use of clinical specimens based on clinical and scientific insight relevant to human disease.

**11:30 The Role of Biobanks in Moving Precision Medicine Forward**
*Nazneen Aziz, Ph.D., Executive Director, Kaiser Permanente Research Bank*
Kaiser Permanente Research Bank (KPRB) is the second largest biobank in the U.S. with goals of enrolling 500,000 participants representing membership in all seven Kaiser Permanente regions. KPRB is one of the largest and most diverse

# 2017 CURRENT AGENDA

repositories of biospecimens, genetic, EMR and health survey data. The KPRB was created to impact the healthcare of KP members and is using precision medicine approaches to accomplish that goal.

**12:00 pm How Biobanking Changed My Bereavement**

*Sarah Gray, Director, Communications, American Association of Tissue Banks; Author, A Life Everlasting: The Extraordinary Story of One Boy's Gift to Medical Science*

Gray shares the now world-famous story of how she anonymously donated her infant son's post-mortem tissue for research, then years later, tracked down each donation to learn about the impact. She discusses her surprising findings and shares her unique perspective on biobanking and biospecimen donation.

**12:30 Book Signing with Sarah Gray**

*A Life Everlasting: The Extraordinary Story of One Boy's Gift to Medical Science*

*Book will be available for purchase onsite

**1:00 Enjoy Lunch on Your Own**

## BIOSPECIMEN SCIENCE

**2:15 Chairperson's Remarks**

*Mary Kay Washington, M.D., Ph.D., Professor, Pathology, Vanderbilt University Medical Center*

---

**2:20 FEATURED PRESENTATION: Factors Affecting the Use of Human Tissues in Research: What the Literature Should Tell Biorepositories**

*William E. Grizzle, M.D., Ph.D., Professor, Pathology, University of Alabama at Birmingham*

This presentation discusses why specimens from biorepositories may not meet the needs of investigators and may fail to produce reproducible results. Topics include patient variables, bias, fixation and tissue processing, storage, quality control, and warm and cold ischemia. How biorepositories can optimally meet investigator needs is a major theme.

---

**2:50 Next-Level Biobanking: Increasing Medical Value with New Tools for Tissue Preservation**

*Abbey Theiss, MS, Senior Scientist, tRED Research and Early Development, Ventana Medical Systems, Inc.*

Cancer diagnostics is rapidly moving to advanced assays to determine drivers of disease. Current non-standardized pre-analytic techniques are inadequate to keep up with the demands of advanced assays. We have investigated formalin chemistry to standardize tissue collection, allowing rapid preservation of an increased number and class of biomarkers. This enables biobanks to create elite tissue sets based on molecular integrity, medical value and verified collection parameters.

**3:20 Selected Poster Presentation: Quality Evaluation for Biobanking Human Granulosa Cells**

*Sahar Jahangiri, MSc, Biobank Manager, CReATe Program, Inc.*

**3:35 Refreshment Break in the Exhibit Hall with Poster Viewing**

**4:00 Conditional Reprogramming (CR): Bringing Biobanks to Life**

*Xuefeng Liu, M.D., Associate Professor, Pathology, Georgetown University*

We describe conditional reprogramming (CR) that rapidly expands both normal and malignant epithelial cells from diverse anatomic sites and mammalian species and does not require transfection with exogenous viral or cellular genes. The ability to produce inexhaustible cell populations from small biopsies and frozen tissue has the potential to transform biobanking repositories by enabling genetic, biochemical, metabolomic, proteomic, and biological assays, including chemosensitivity testing.

**4:30 Steps of Research and Development - "Live Biobank"**

*Zdenka Prodanovic, Biobank Manager, Pathology, Monash Health*

We discuss managing a biobank to facilitate translational research in pioneering efforts toward precision medicine by establishing a "live biobank". We share latest diagnostic molecular developments and the ongoing impact on patient treatments, which call for a "live biobank" setup. Organoid cultures could hold an answer. A "live biobank" may prove to be, among other uses, one of the most important research tools in cancer/other diseases. How far its impact may reach is yet to be seen.

**5:00 The Importance of Centralized and Harmonized Biobanking to Support Precision Medicine Initiatives**

*Andrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University*

This presentation describes how to standardize biobanking efforts in a manner commensurate with both academic and industrial partnerships. Data will be presented on the governance of biosample collections, standardization efforts, and quality control harmonization for biosamples and global best practices for the regulatory oversight of national biobank resources.

**5:30 Welcome Reception in the Exhibit Hall with Poster Viewing**

**6:45 Close of Day**

## FRIDAY, OCTOBER 27

**7:30 am Biobanking Brainstorming Breakfast Discussion Groups**

Grab a cup of coffee and join a discussion group. These are moderated discussions with brainstorming and interactive problem solving, allowing conference participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic.

*For more details, please visit BiobankingCongress.com*

**8:45 Close of Discussion Groups**

## APPLYING BIOSPECIMENS FOR TRANSLATIONAL RESEARCH

**9:00 Chairperson's Remarks**

*James R. Goldenring, M.D., Ph.D., AGAF, Paul W. Sanger Professor of Surgery, Professor of Cell and Developmental Biology, Vice Chairman for Research, Surgical Sciences, Vanderbilt University School of Medicine*

**9:05 The Fibrotic Microenvironment in Pancreatic Cancer and Chronic Pancreatitis**

*Anna L. Means, Ph.D., Associate Professor, Department of Surgery, Vanderbilt University Medical Center*

Pancreatic cancer and chronic pancreatitis involve large fibrotic responses with variable functions in benign and malignant disease. Using biobanked tissues, we have identified similar and unique fibrotic elements occurring in pancreatic cancer and in benign disease. We are using freshly acquired tissue to identify regulatory pathways specific to the pro-tumor functions of the microenvironment that don't weaken constraints on tumor dissemination.

# 2017 CURRENT AGENDA

**9:35 Biobank Supporting Translational Research for Rare Disease: The BioMarin Model**

*Feng Hong, Ph.D., Associate Director, Clinical Biospecimen Management, BioMarin Pharmaceutical, Inc.*

We discuss rare disease, where unmet medical need drives expedited drug development and more extensive post-marketing assessments; smaller sample size; dearth of commercial samples; and the need to support post-marketing assessments, which lead to more scrutiny on the strategy of translational science research.

**10:05 Coffee Break in the Exhibit Hall with Poster Viewing**

**10:45 Precision Pathology: Banking on Theranostics and Beyond**

*Michael Roehrl, M.D., Ph.D., Director, Precision Pathology Biobanking Center, Memorial Sloan Kettering Cancer Center*

The talk will explain the concept of Precision Pathology and describe the new Center created at Memorial Sloan Kettering Cancer Center. Pathology plays a central and decisive role in design and execution of specimen-centered precision clinical trials, drug development, and theranostic innovation.

**11:15 Case Study Co-Presentation:**

*Sponsored by*

Brooks Life Science Systems | BioProcessing Solutions powered by RUCDR

## BROOKS LIFE SCIENCE SYSTEMS

**Sample Management Innovations for Precision Medicine Initiatives**

*Andrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; CSO, BioProcessing Solutions Alliance; Rutgers University*

*Angela Dobes, MPH, Senior Director, IBD Plexus, Crohn's & Colitis Foundation*

Biomarkers are driving our understanding of both disease and risk stratification. The RISK Study led by the Crohn's and Colitis Foundation is comprised of the largest well-characterized group of pediatric patients in the history of Crohn's disease research. More than 1,800 participants, ages 6 to 17, were recruited at disease onset, and 913 are being prospectively followed for complications and response to therapies. Biological samples are collected from 28 clinics along with clinical, demographic, immunological, and genetic data. Data and biosamples can be used in drug targets and biomarker discovery, characterization of changes in microbiome and transcriptome, hypothesis and evidence generation, and comparative effectiveness research. Centralized biobanking and sample preparation services are a key component to the quality of the RISK Study and this approach positions the role of Sample Lifecycle Management as an enabler at the beginning of an R&D value chain. Similar projects in life sciences discovery initiatives focused on investigating biomarker transitions will be able to realize incremental benefits as they embrace innovations in samples lifecycle management.

**12:00 pm Session Break**

**12:15 Luncheon Presentation** *(Sponsorship Opportunity Available)*
**or Enjoy Lunch on Your Own**

**1:30 Dessert Break in the Exhibit Hall**

## BIOSPECIMENS LEAD TO PRECISE MEDICINE

**2:00 Chairperson's Remarks**

*James R. Goldenring, M.D., Ph.D., AGAF, Paul W. Sanger Professor of Surgery, Professor of Cell and Developmental Biology, Vice Chairman for Research, Surgical Sciences, Vanderbilt University School of Medicine*

**2:05 Use of Biospecimens in Clinical Research**

*Mary E. Edgerton, M.D., Ph.D., Associate Professor, Department of Pathology, University of Texas MD Anderson Cancer Center*

When does clinical research involve a clinically actionable test on a biospecimen that is not a part of the clinical specimen archive? What does that mean for patient safety? How important is it for that specimen to be CLIA (Clinical Laboratory Improvements Amendment of 1988)-compliant? What steps should be taken to make a biorepository CLIA compliant? What are the pro's and con's of taking this approach to ensure patient safety in the use of biospecimens in clinical research? Is it always necessary? These questions will be introduced and the process for establishing a CLIA-compliant biospecimen repository will be described using the MD Anderson Institutional Tissue Bank as an example.

**2:35 Enabling Systems Toxicology Assessment Studies with State-of-the-Art Biospecimen Management Systems**

*Sam Ansari, Ph.D., Manager, Biospecimen & LIMS, Biomedical Research, Philip Morris International R&D*

Systems Toxicology is an emerging assessment approach based on a variety of high-throughput molecular measurements. These experiments often involve large sample sizes, require rich sample annotations, and cause many sample events leading to complex sample relationships. Sophisticated sample management is key to a successful experimental outcome. In a case study, we demonstrate the full lifecycle of study samples and present our technical solutions.

**3:05 Co-Presentation:**

## MAYO CLINIC BIOBANK

**Biobanker Experience: Building and Facilitating Use of the Mayo Clinic Biobank**

*James R. Cerhan, M.D., Ph.D., Professor of Epidemiology, Mayo Clinic College of Medicine and Science, Health Sciences Research, Mayo Clinic*

**Biouser Experience: Use of the Mayo Clinic Biobank for Pharmacogenomic Clinical Implementation and Discovery**

*Suzette J. Bielinski, Ph.D., Associate Professor of Epidemiology, Mayo Clinic College of Medicine and Science, Health Sciences Research, Mayo Clinic*

The Mayo Clinic Biobank was launched in 2009 as a general use resource for scientific investigations. Through 2015, over 50,000 participants were enrolled with banked DNA, serum/plasma, questionnaire data and prospective access to the electronic health record. To date, over 200 researchers have used the Biobank, including a large research program for pharmacogenomic discovery and clinical implementation.

# FINAL WEEKSTO REGISTER



Register Online!
**biobankingcongress.com**

# 2017 CURRENT AGENDA

**3:50 Co-Presentation:**

## VANDERBILT UNIVERSITY

**Biobanker Experience: The Academic Biorepository's Responsibility: The Ultimate Agile Resource**

*Mary Kay Washington, M.D., Ph.D., Professor, Pathology, Vanderbilt University Medical Center*

*Kerry R. Wiles, Program Director, Cooperative Human Tissue Network and Vanderbilt University Medical Center Tissue Repository, Vanderbilt University*

**Biouser Experience: Investing at the Biobank Will Yield Dividends: Understanding Mechanisms of Patient Response to Immunotherapy**

*Katy Beckermann, M.D., Ph.D., Chief Academic Fellow, Division of Hematology/ Oncology, Vanderbilt University Medical Center, Vanderbilt University*

The academic biorepository can be compared to a house built on shifting sands for those managing the resource. Repository managers often wear multiple hats, and the process requires customer participation, communicating current needs and scope changes of research projects quickly, and staff working towards streamlining processes and implementing changes quickly, to minimize impact on the customer project. The biorepository's responsibility includes working through project scope and assisting with IRB submissions, which may prevent project-adverse difficulties.

**4:35 Conference Wrap-Up**

*Mary Ann Brown, Executive Director, Conferences, Cambridge Healthtech Institute*

*Kerry R. Wiles, Program Director, Cooperative Human Tissue Network and Vanderbilt University Medical Center Tissue Repository, Vanderbilt University*

**4:45 Close of Conference**

# HOTEL & TRAVEL INFORMATION

**Conference Venue and Hotel:**

Nashville Marriott at Vanderbilt University
2555 West End Avenue
Nashville, TN 37203
Tel: 615-321-1300

**Discounted Room Rate: $214 s/d**
**Discounted Room Rate**
**Cut-off Date: September 27, 2017**

**RESERVATIONS AND ADDITIONAL TRAVEL INFORMATION:**
Please visit the travel page of **BiobankingCongress.com**

FINAL WEEKSTO REGISTER



Register Online!
**biobankingcongress.com**

# Sponsor, Exhibit Opportunities and Lead Generation

CHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space, branding and networking with specific prospects. Sponsorship allows you to achieve your objectives before, during, and long after the event. Any sponsorship can be customized to meet your company's needs and budget. Signing on early will allow you to maximize exposure to qualified decision-makers.

## Podium Presentations

***— Available within Main Agenda!***

Showcase your solutions to a guaranteed, targeted audience through a 15- or 30-minute presentation during a specific conference program, breakfast, lunch, or separate from the main agenda within a pre-conference workshop. Package includes exhibit space, on-site branding, and access to cooperative marketing efforts by CHI. For the luncheon option, lunches are delivered to attendees who are already seated in the main session room. Presentations will sell out quickly, so sign on early to secure your talk!

## Invitation-Only VIP Dinner/ Hospitality Suite

Sponsors will select their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects, helping you to make the most out of this invaluable opportunity. Evening will be customized according to sponsor's objectives i.e.:

- Purely social
- Focus group
- Reception style
- Plated dinner with specific conversation focus

## Exhibit

Exhibitors will enjoy facilitated networking opportunities with qualified delegates. Speak face-to-face with prospective clients and showcase your latest product, service, or solution.

## One-on-One Meetings

Select your top prospects from the pre-conference registration list. CHI will reach out to your prospects and arrange the meeting for you. A minimum number of meetings will be guaranteed, depending on your marketing objectives and needs. A very limited number of these packages will be sold.

## Additional branding and promotional opportunities are available, including:

- Conference Tote Bags
- Literature Distribution (Tote Bag Insert or Chair Drop)
- Badge Lanyards
- Padfolios
- Program Guide Advertisement

## Looking for additional ways to drive leads to your sales team?

CHI's Lead Generation Programs will help you obtain more targeted, quality leads throughout the year. We will mine our database of 800,000+ life science professionals to your specific needs. We guarantee a minimum of 100 leads per program! Opportunities include:

- Whitepapers
- Web Symposia
- Custom Market Research Surveys
- Podcasts

**BiobankingCongress.com**



**For additional information, please contact:** **Carolyn Benton** | Business Development Manager
(+1) 781-972-5412 **cbenton@healthtech.com**



Cambridge HEALTHTECH Institute
A Division of Cambridge Innovation Institute

FINAL WEEKSTO REGISTER



# Leaders in BIObanking Congress 2017

October 25-27, 2017 | Nashville, TN | Nashville Marriott at Vanderbilt University

## How to Register: BiobankingCongress.com

Please use keycode **BNK F** when registering!

reg@healthtech.com • P: (+1) 781-972-5400 or Toll-free in the U.S. (+1) 888-999-6288

## PRICING AND REGISTRATION INFORMATION

### SHORT COURSES

| | Commercial | Academic, Government, Hospital-affiliated |
|---|---|---|
| One short course | $699 | $399 |
| Two short courses | $999 | $699 |

Select which short course you would like to attend:

| Wednesday, October 25: 8:30-11:30am | Wednesday, October 25: 12:30-3:30pm |
|---|---|
| ❑ SC1: From Donor to Discovery - Post-Mortem Sample Biobanking | ❑ SC2: Lean Six Sigma and the Biorepository - Synchronicity in the Simplest Form |

### CONFERENCE PRICING

**STANDARD PACKAGE** *(Includes access to Leaders in Biobanking Congress and Onsite Tour, excludes Short Course(s))*

| | | |
|---|---|---|
| Registrations after September 22, 2017, and on-site | $2199 | $1049 |

❑ Yes, I will attend the Onsite Tour. *(Included in Registration. Tour limited to first 50 participants.)*

### CONFERENCE DISCOUNTS

**Poster Submission - Discount ($50 Off)**: Poster abstracts are due by September 22, 2017. Once your registration has been fully processed, we will send an email containing a unique link allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact jring@healthtech.com. *CHI reserves the right to publish your poster title and abstract in various marketing materials and products.

**REGISTER 3 - 4th IS FREE:** Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply.

**Alumni Discount:** Cambridge Healthtech Institute (CHI) appreciates your past participation at Leaders in Biobanking Congress. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registration rate.

**Group Discounts:** Discounts are available for multiple attendees from the same organization. For more information on group rates contact Jeff Knight, jknight@healthtech.com at (+1) 781-247-6264.

If you are unable to attend but would like to purchase the Leaders in BioBanking Congress CD for $350 (plus shipping), please visit BiobankingCongress.com. Massachusetts delivery will include sales tax.


Cambridge HEALTHTECH Institute

A Division of Cambridge Innovation Institute

250 First Avenue, Suite 300
Needham, MA 02494
Healthtech.com
Fax: 781-972-5425




**ADDITIONAL REGISTRATION DETAILS**

Each registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.

Handicapped Equal Access: In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

**To view our Substitutions/Cancellations Policy, go to healthtech.com/regdetails**

Video and or audio recording of any kind is prohibited onsite at all CHI events.